EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment

Taketo Ezaki, Toshihide Tanaka, Ryota Tamura, Kentaro Ohara, Yohei Yamamoto, Jun Takei, Yukina Morimoto, Ryotaro Imai, Yuki Kuranai, Yasuharu Akasaki, Masahiro Toda, Yuichi Murayama und 2 weitere

Brain Tumor Pathology · 2024

DOI: 10.1007/s10014-024-00481-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Tumor Pathology, 2024. Verfasst von Taketo Ezaki und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan. Hauptthemen laut MEDLINE: Glioblastoma, Bevacizumab, Brain Neoplasms, Neovascularization, Pathologic. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Promotion of Material Science and Technology of Japan, Jikei University School of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme (GBM) acquires resistance to bevacizumab (Bev) treatment. Bev affects angiogenic factors other than vascular endothelial growth factor (VEGF), which are poorly understood. We investigated changes in angiogenic factors under and after Bev therapy, including angiopoietin-1 (ANGPT1), angiopoietin-2 (ANGPT2), placental growth factor (PLGF), fibroblast growth factor 2, and ephrin A2 (EphA2). Fifty-four GBM tissues, including 28 specimens from 14 cases as paired specimens from the same patient obtained in three settings: initial tumor resection (naïve Bev), tumors resected following Bev therapy (effective Bev), and recurrent tumors after Bev therapy (refractory Bev). Immunohistochemistry assessed their expressions in tumor vessels and its correlation with recurrent MRI patterns. PLGF expression was higher in the effective Bev group than in the naïve Bev group ( p = 0.024) and remained high in the refractory Bev group. ANGPT2 and EphA2 expressions were higher in the refractory Bev group than in the naïve Bev group ( p = 0.047 and 0.028, respectively). PLGF expression was higher in the refractory Bev group compared with the naïve Bev group for paired specimens ( p = 0.036). PLGF was more abundant in T2 diffuse/circumscribe patterns ( p = 0.046). This is the first study to evaluate angiogenic factors other than VEGF during effective and refractory Bev therapy in patient-derived specimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBevacizumabBrain NeoplasmsNeovascularization, PathologicAngiopoietin-2Angiogenesis InhibitorsHumansMaleFemaleMiddle AgedAgedAdultPlacenta Growth FactorAntineoplastic Agents, ImmunologicalAngiopoietin-1Neoplasm Recurrence, Local

Stichwörter der Autor:innen

Alternative angiogenesis factorBevacizumabGlioblastomaVascular endothelial growth factor

Substanzen

BevacizumabAngiopoietin-2Angiogenesis InhibitorsPlacenta Growth FactorPGF protein, humanANGPT2 protein, humanAntineoplastic Agents, ImmunologicalAngiopoietin-1

Autor:innen und Institutionen

  • Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
  • Department of Neurosurgery, The Jikei University School, of Medicine Kashiwa Hospital, 163-1 Kashiwashita, Kashiwa-shi, Chiba, 277-8567, Japan. ttanaka@jikei.ac.jp.
  • Department of Neurosurgery, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-Ku, Tokyo, 105-8461, Japan. ttanaka@jikei.ac.jp.
  • Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
  • Department of Neurosurgery, The Jikei University School of Medicine Daisan Hospital, 4-11-1 Izumi-Motomachi, Komae-Shi, Tokyo, 201-8601, Japan.
  • Department of Neurosurgery, The Jikei University School of Medicine Katsushika Medical Center, 6-41-2 Aoto, Katsushika-Ku, Tokyo, 125-8506, Japan.

Förderung

  • Foundation for Promotion of Material Science and Technology of Japan
  • Jikei University School of Medicine

Zitieren

APA

Ezaki, T., Tanaka, T., Tamura, R., Ohara, K., Yamamoto, Y., Takei, J., Morimoto, Y., Imai, R., Kuranai, Y., Akasaki, Y., Toda, M., Murayama, Y., Miyake, K., & Sasaki, H. (2024). Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. Brain Tumor Pathology. https://doi.org/10.1007/s10014-024-00481-0

Vancouver

Ezaki T, Tanaka T, Tamura R, Ohara K, Yamamoto Y, Takei J, et al. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. Brain Tumor Pathology. 2024. doi:10.1007/s10014-024-00481-0

BibTeX
@article{Ezaki2024,
  author = {Ezaki, Taketo and Tanaka, Toshihide and Tamura, Ryota and Ohara, Kentaro and Yamamoto, Yohei and Takei, Jun and Morimoto, Yukina and Imai, Ryotaro and Kuranai, Yuki and Akasaki, Yasuharu and Toda, Masahiro and Murayama, Yuichi and Miyake, Keisuke and Sasaki, Hikaru},
  title = {Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment},
  journal = {Brain Tumor Pathology},
  year = {2024},
  doi = {10.1007/s10014-024-00481-0}
}
Kostenlos starten →